AMO Pharma Limited   Report issue

For profit Phase 3
Founded: Wonersh United Kingdom (2015)

Organization Overview

First Clinical Trial
2016
NCT02858908
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

AMO Pharma | AMO Pharma Limited

Active Ingredients

Drugs in Phase 3 Trials (1)

tideglusib (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myotonic Dystrophy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1